VERTEX INVESTOR EVENT AT THE AMERICAN SOCIETY OF NEPHROLOGY KIDNEY WEEK 2026 - CRINETICS PHARMACEUTICALS INC

Explicit Guidance:

• Povitacicept (POVI) FDA Approval: Anticipated PDUFA date is November 30 (year implied as 2026 based on context of "ASD 2026 Kidney Week" and "early next year" timeline). Management is in active engagement with the FDA regarding label specifics and monitoring requirements.
• Amplified (Innersaplin) Interim Analysis: Interim results expected early next year (early 2027). The analysis population is estimated to include ~200 patients out of a total enrollment of 522.
• Reimbursement/Coverage Timeline: Commercial coverage announcements expected in the first half of 2027. A bridge program will be active prior to formal coverage to facilitate patient access.
• Regulatory Endpoint Strategy: For the Amplitude study, FDA agreement for potential accelerated approval is based on a one-year GFR endpoint. Management expects the one-year GFR data to be statistically significant and less noisy due to the rapid progression rate of AMKD (5–8 mL/min/year).

Business-Segment Outlook:

• Renal Pipeline Inflection:
  • POVI (IGAN & Membranous): Positioned as the company's first renal medicine; Phase 3 interim analysis shows 52% reduction in proteinuria at 36 weeks, with near 80% reduction in galactose-deficient IgA1 and >80% hematuria resolution. Anticipated to become a $10 billion franchise alongside CF.
  • Innersaplin (AMKD): Phase 3 "Amplified" study fully enrolled (522 patients). Phase 2 "Amplified" data (Cohort 2: diabetic nephropathy + AMKD) showed 17–25% reduction in proteinuria.
  • ADPKD: Small molecule in Phase 2 proof-of-concept; targeting a misfolded protein similar to CF mechanism. Initial approach covers 35,000 of the 350,000 total ADPKD patients.
• Geography & Partnerships:
  • China/Asia: Zai Therapeutics handles marketing.
  • Japan: Ono Pharmaceutical handles marketing.
  • US/Europe: Vertex manages commercialization directly.
• Patient Populations: AMKD eligible population estimated by management at 250,000–350,000 in the US; Dr. Ojo estimates 600,000–700,000. IGAN population cited as >1 million globally (high prevalence in Asia).

Market and Competitive Outlook:

• Product Differentiation: POVI's once-monthly, small-volume auto-injector format is positioned as superior to competitors' pre-filled syringes or frequent dosing, expected to drive high patient preference and uptake.
• Competitive Landscape: Management views B-cell modulators (POVI) as potentially superior to complement inhibitors for controlling complement activation due to superior proteinuria reduction (52% for POVI vs. "half as good" GFR data seen with TACOPAN).
• Switch Dynamics: Expect primary patient acquisition from the untreated market (approx. 148,000 of 150,000 IgAN patients) rather than switching existing users, though technical switches are feasible if price differentials are not prohibitive.
• Payer Access: No expectation of step therapy requiring trial of other B-cell inhibitors before POVI approval. Payers cited as having an "incredibly positive" reaction to the product's convenience and efficacy.

Macro / Industry Outlook:

• Regulatory Trends: Anticipation of a shift from GFR-based endpoints to proteinuria-based endpoints in AMKD (similar to the recent shift in IGAN), though current FDA agreement remains GFR-focused.
• Standard of Care: Clinical trial populations are increasingly on background therapy (RAS inhibitors, SGLT2 inhibitors, MRAs), setting a higher bar for demonstrating incremental benefit.
• Long-term Usage: Expectation that B-cell modulators will be viewed as long-term commitments (potentially 5+ years in extensions) rather than short-term use, with "drug holidays" only considered under specific clinical scenarios (e.g., pregnancy).

Strategic Initiatives:

• Commercial Readiness: Engagement with PBMs and payers began July 2025 to secure coverage, prioritizing the 70% commercial patient base.
• Product Formulation: POVI engineered specifically for low volume, low viscosity for auto-injector delivery to maximize patient adherence; available in pre-filled syringes during trials, transitioning to auto-injector at launch.
• Pipeline Expansion: Exploration of B-cell modulators in non-renal indications (e.g., Myasthenia Gravis).

Risks and Headwinds to Outlook:

• Regulatory Uncertainty: Final label details and monitoring requirements (e.g., specific to complement inhibitors vs. B-cell modulators) are pending FDA negotiation.
• Data Correlation: While proteinuria reduction is a strong surrogate, final confirmation of GFR protection requires long-term data (beyond the 36-week interim).
• Real-World Efficacy: Uncertainty remains regarding long-term "off-drug" activity and GFR decline post-discontinuation; current data is limited to short-term observations.
• Cohort Heterogeneity: In the diabetic AMKD cohort (Cohort 2), proteinuria reduction was modest (17–25%) compared to Cohort 1, as Innersaplin treats AMKD but not the concurrent diabetic nephropathy, potentially diluting clinical benefit signals.

Management Tone on the Future:

• Confidence Level: High. Management describes POVI data as "transformational," "beautiful," and "monumental." Confidence in the one-year GFR endpoint for AMKD is explicitly stated as "high degree of confidence."
• Strategic Pivot: Strong emphasis on the company's evolution from a "CF company" to a "renal company," viewing the renal franchise as a potential $10 billion growth engine comparable to CF.
• Hedges: Caution noted regarding "drug holidays" and the need for long-term extension data before confirming off-drug safety profiles.

Miscellaneous:

• Safety Profile: POVI demonstrated safety "identical to placebo" in interim analysis with no deaths; adverse events were generally low, with injection site reactions being mild and infrequent.
• Patient Preference: Data suggests patients strongly prefer infrequent dosing (monthly) and auto-injectors over weekly injections or manual pre-filled syringes.